Intravitreal bevacizumab for posterior capsule neovascularization

1Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We report a case of rapid regression of extensive posterior capsule neovascularization in a 67-year-old diabetic male patient, who developed posterior capsule opacity with neovascularization one year post cataract surgery, after a single injection of intravitreal bevacizumab (Avastin) followed by neodymium:YAG capsulotomy. Rapid regression of the posterior capsule neovascularization, and visual improvement was observed 9 days after the intervention. Posterior capsulotomy was performed successfully without bleeding. Prior to posterior capsulotomy, intravitreal bevacizumab can result in rapid and dramatic regression of posterior capsule neovascularization. © 2009 King Saud University.

Cite

CITATION STYLE

APA

Al-Mohaimeed, M., Al-Gehedan, S., & Dhibi, H. A. (2010). Intravitreal bevacizumab for posterior capsule neovascularization. Saudi Journal of Ophthalmology, 24(2), 63–65. https://doi.org/10.1016/j.sjopt.2010.02.002

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free